SageView Advisory Group
JANX icon

SageView Advisory Group’s Janux Therapeutics JANX Stock Holding History

SageView Advisory Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-950
Closed -$13.1K – 1523
2025
Q4 		$13.1K Buy
+950
New +$22.3K ﹤0.01% 1614

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SageView Advisory Group's JANX Position: Q1 2026 in Review

SageView Advisory Group sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 950 shares — an estimated $13.1K sold.

SageView Advisory Group first reported a position in JANX in Q4 2025 and held it in 1 quarter. The position peaked at $13.1K in Q4 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • SageView Advisory Group reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 950 Janux Therapeutics shares in Q1 2026, an estimated $13.1K.
  • SageView Advisory Group first reported a position in Janux Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Janux Therapeutics position peaked at $13.1K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.